United Therapeutics Corporation
UTHR
$477.07
-$2.88-0.60%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.43% | -3.94% | 6.94% | -2.52% | 11.15% |
| Total Depreciation and Amortization | 3.79% | 6.57% | 0.51% | 3.14% | 2.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.16% | 55.58% | 68.85% | -32.22% | -18.55% |
| Change in Net Operating Assets | 180.05% | -360.26% | 1,957.14% | -132.31% | 111.95% |
| Cash from Operations | 193.22% | -58.43% | 35.17% | -9.54% | 62.45% |
| Capital Expenditure | -238.42% | 16.96% | 13.61% | -13.33% | -69.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 247.83% | -164.70% | -146.03% | 4.95% | -10.03% |
| Cash from Investing | 146.98% | -82.09% | -33.69% | -7.22% | -43.63% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -300.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 145.86% | -15.81% | -16.02% | -29.48% | -30.33% |
| Repurchase of Common Stock | -19,140.38% | 66.01% | -5,000.00% | 25.00% | -300.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | -381.37% | -111.73% | -25.57% | -16.54% | -33.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.54% | -251.36% | 41.45% | -27.70% | 90.21% |